Dr. Matasar on Antibody-Drug Conjugates in B-Cell Malignancies

Matthew J. Matasar, MD
Published: Thursday, Jul 13, 2017



Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates (ADCs) in B-cell malignancies.

Polatuzumab vedotin, an ADC, is being studied in combination with rituximab (Rituxan) or obinutuzumab (Gazyva) in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL).

As for ADCs in this space, there has been success with brentuximab vedotin, which is approved by the FDA in classical Hodgkin lymphoma.
 
SELECTED
LANGUAGE


Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates (ADCs) in B-cell malignancies.

Polatuzumab vedotin, an ADC, is being studied in combination with rituximab (Rituxan) or obinutuzumab (Gazyva) in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL).

As for ADCs in this space, there has been success with brentuximab vedotin, which is approved by the FDA in classical Hodgkin lymphoma.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x